GSK discusses pipeline expectations, growing HIV sales

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) CEO Andrew Witty said on the company's 2Q15 earnings call that the company has about 40 drug candidates in its pipeline, with 20-25 that could be approved in the next five years. The company expects to unveil more details at its R&D day in November.

GSK also said ViiV Healthcare, its HIV-focused joint venture with Pfizer Inc. (NYSE:PFE) and Shionogi & Co. Ltd. (Tokyo:4057), had L559 million ($867 million) in 2Q15 sales, up 59% from L352 million ($545.9 million) in 2Q14. GSK opted to retain its stake in ViiV after considering a spin-off via an IPO (see BioCentury Extra, May 6). ...